SINOMED(SH:688108) Zheng Quan Zhi Xing·2025-08-21 10:22Core Viewpoint - Sino Medical Science and Technology Co., Ltd. reported a significant increase in revenue and net profit for the first half of 2025, indicating a positive trend in its financial performance [1][3]. Financial Summary - Total assets at the end of the reporting period reached approximately 1.31 billion RMB, a 0.70% increase from the previous year [3]. - Revenue for the reporting period was approximately 240.48 million RMB, reflecting a 12.53% increase compared to the same period last year [3]. - The total profit amounted to approximately 23.01 million RMB, a significant recovery from a loss of approximately 4.74 million RMB in the previous year [3]. - Net profit attributable to shareholders was approximately 13.84 million RMB, a substantial increase of 296.54% compared to 3.49 million RMB in the same period last year [3]. - The net cash flow from operating activities was approximately 52.45 million RMB, a 303.38% increase from 13.00 million RMB in the previous year [3]. Shareholder Information - The total number of shareholders at the end of the reporting period was 11,090 [4]. - The top shareholder, Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd., holds 5.47% of the shares [4]. - Other significant shareholders include Huang Songlang with 2.62% and Tianjin Sunshine Guangye Enterprise Management with 2.55% [4]. Profitability Metrics - The weighted average return on equity increased to 1.58%, up by 1.16 percentage points from 0.42% [4]. - Basic and diluted earnings per share were both reported at 0.03 RMB, an increase of 200% from 0.01 RMB [4]. Research and Development - The proportion of R&D investment relative to revenue was 32.36%, a decrease of 10.80 percentage points from 43.16% in the previous year [4].